{
  "@context": [
    "file://domain/_contexts/base.jsonld",
    "file://domain/_contexts/medicine.jsonld"
  ],
  "@type": [
    "EducationalResource",
    "MedicalGuideline"
  ],
  "@id": "health-sciences:medicine:cardiology:cardio-005",
  "metadata": {
    "version": "4.0.0",
    "created": "2026-01-09T01:50:10.000Z",
    "contributors": [
      "copilot-agent",
      "quality-enhancement-agent",
      "cardiology-knowledge-base"
    ],
    "confidence": 0.97,
    "status": "validated",
    "modified": "2026-01-11T14:28:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/cardiology",
    "type": "treatment",
    "difficulty": "advanced",
    "importance": "critical",
    "aku_id": "005",
    "keywords": [
      "HFrEF",
      "heart failure",
      "GDMT",
      "ACE inhibitor",
      "beta-blocker",
      "ARNI",
      "SGLT2 inhibitor"
    ],
    "medical_specialty": "cardiology",
    "clinical_context": "heart_failure"
  },
  "content": {
    "title": "HFrEF Treatment (Guideline-Directed Medical Therapy)",
    "summary": "Evidence-based pharmacotherapy for heart failure with reduced ejection fraction",
    "key_points": [
      "Four pillars: ARNI/ACEi + Beta-blocker + MRA + SGLT2i",
      "Quadruple therapy reduces mortality ~75% vs placebo",
      "Initiate all four drug classes early, titrate to target doses",
      "Add hydralazine/nitrates in African Americans",
      "Ivabradine if HR >70 despite max beta-blocker",
      "ICD if EF \u226435% after 3 months GDMT"
    ],
    "statement": {
      "text": "HFrEF treatment consists of four foundational drug classes (ARNI or ACEi, beta-blocker, MRA, SGLT2i) that reduce mortality and hospitalizations. All four should be initiated early and titrated to target doses. Device therapy (ICD, CRT) is added based on EF and ECG criteria after optimal medical therapy.",
      "formal": "HFrEF GDMT = (ARNI or ACEi/ARB) + Beta-blocker + MRA + SGLT2i \u2192 Target doses \u2192 Consider ICD/CRT"
    },
    "explanation": {
      "intuition": "HFrEF treatment counteracts the harmful neurohormonal activation (RAAS, sympathetic) that drives disease progression. Each drug class blocks a different harmful pathway - together they're synergistic. Think of it as putting out a fire with multiple extinguishers.",
      "key_insight": "The paradigm has shifted from sequential addition to early initiation of all four classes. Don't wait to 'maximize' one drug before starting another - start all four early at low doses, then uptitrate.",
      "technical_details": "Target doses are evidence-based from landmark trials: enalapril 10-20mg BID (CONSENSUS, SOLVD), carvedilol 25mg BID (COPERNICUS), spironolactone 25-50mg daily (RALES), sacubitril/valsartan 97/103mg BID (PARADIGM-HF), dapagliflozin 10mg daily (DAPA-HF)."
    },
    "definitions_glossary": {
      "GDMT": "Guideline-directed medical therapy - evidence-based treatments proven to reduce mortality",
      "ARNI": "Angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan)",
      "ACE_inhibitor": "Angiotensin-converting enzyme inhibitor; blocks RAAS",
      "ARB": "Angiotensin receptor blocker; alternative to ACEi",
      "MRA": "Mineralocorticoid receptor antagonist (spironolactone, eplerenone)",
      "SGLT2_inhibitor": "Sodium-glucose cotransporter-2 inhibitor; benefits HF independent of glucose-lowering",
      "beta_blocker": "Beta-adrenergic receptor antagonist; reduces sympathetic activation",
      "target_dose": "Dose proven effective in clinical trials, goal of titration",
      "ICD": "Implantable cardioverter-defibrillator for sudden death prevention",
      "CRT": "Cardiac resynchronization therapy for dyssynchrony in LBBB",
      "neurohormonal_blockade": "Pharmacologic inhibition of RAAS and sympathetic nervous system",
      "reverse_remodeling": "Improvement in LV size and function with effective therapy"
    }
  },
  "clinical_features": {
    "pathophysiology": {
      "therapeutic_targets": {
        "RAAS": "ACEi/ARB/ARNI block angiotensin II effects; MRA blocks aldosterone",
        "sympathetic": "Beta-blockers reduce catecholamine-mediated damage",
        "natriuretic_peptides": "ARNI enhances protective natriuretic peptide effects",
        "SGLT2": "Multiple mechanisms: diuresis, improved energetics, reduced preload"
      }
    },
    "treatment_options": {
      "first_line_drugs": {
        "ARNI": {
          "drug": "Sacubitril/valsartan (Entresto)",
          "starting_dose": "24/26mg or 49/51mg BID",
          "target_dose": "97/103mg BID",
          "key_trial": "PARADIGM-HF: 20% RRR mortality vs enalapril",
          "notes": "36-hour washout from ACEi to avoid angioedema"
        },
        "ACE_inhibitor": {
          "drugs": "Enalapril, lisinopril, ramipril",
          "target_doses": "Enalapril 10-20mg BID, Lisinopril 20-40mg daily",
          "key_trials": "CONSENSUS, SOLVD: 16-27% RRR mortality"
        },
        "beta_blocker": {
          "drugs": "Carvedilol, metoprolol succinate, bisoprolol (only these three)",
          "target_doses": "Carvedilol 25-50mg BID, Metoprolol succinate 200mg daily",
          "key_trials": "COPERNICUS, MERIT-HF, CIBIS-II: 34-65% RRR mortality",
          "notes": "Start low, uptitrate every 2 weeks; don't start if decompensated"
        },
        "MRA": {
          "drugs": "Spironolactone, eplerenone",
          "target_doses": "Spironolactone 25-50mg daily, Eplerenone 25-50mg daily",
          "key_trial": "RALES: 30% RRR mortality",
          "monitoring": "Check potassium and creatinine; avoid if K >5.0 or eGFR <30"
        },
        "SGLT2_inhibitor": {
          "drugs": "Dapagliflozin (Farxiga), empagliflozin (Jardiance)",
          "dose": "Dapagliflozin 10mg, Empagliflozin 10mg daily",
          "key_trials": "DAPA-HF, EMPEROR-Reduced: 25% RRR mortality/HF hospitalization",
          "notes": "Benefits regardless of diabetes status; may have euglycemic DKA risk"
        }
      },
      "additional_therapies": {
        "hydralazine_nitrates": {
          "indication": "African Americans with HFrEF (A-HeFT trial)",
          "dose": "Hydralazine 75mg TID + ISDN 40mg TID",
          "also_use": "ACEi-intolerant patients"
        },
        "ivabradine": {
          "indication": "HR >70 despite maximum tolerated beta-blocker, sinus rhythm",
          "mechanism": "Selective If channel blocker - slows HR without BP effect",
          "trial": "SHIFT: 18% RRR CV death/HF hospitalization"
        },
        "diuretics": {
          "role": "Symptom relief for congestion; no mortality benefit",
          "drugs": "Furosemide, torsemide, bumetanide (loops); metolazone (add for resistance)"
        },
        "digoxin": {
          "role": "Symptom improvement, reduced HF hospitalization; no mortality benefit",
          "indication": "Persistent symptoms despite GDMT; AF rate control"
        }
      },
      "device_therapy": {
        "ICD": {
          "indication": "LVEF \u226435% despite \u22653 months GDMT, NYHA II-III, life expectancy >1 year",
          "key_trials": "SCD-HeFT, MADIT-II",
          "notes": "Wait at least 40 days post-MI, 90 days after revascularization"
        },
        "CRT": {
          "indication": "LVEF \u226435%, LBBB, QRS \u2265150ms, NYHA II-IV",
          "benefit": "Improves symptoms, EF, and survival with LBBB morphology",
          "CRT_D_vs_CRT_P": "CRT-D (with ICD) for most; CRT-P if not ICD candidate"
        }
      }
    }
  },
  "skos": {
    "prefLabel": {
      "@language": "en",
      "@value": "HFrEF Treatment"
    },
    "altLabel": [
      {
        "@language": "en",
        "@value": "Heart Failure with Reduced EF Therapy"
      },
      {
        "@language": "en",
        "@value": "Guideline-Directed Medical Therapy for HFrEF"
      }
    ],
    "definition": {
      "@language": "en",
      "@value": "Evidence-based pharmacotherapy and device therapy for heart failure with reduced ejection fraction, comprising four foundational drug classes plus ICD/CRT when indicated"
    },
    "notation": "cardio-005"
  },
  "medicalCode": [
    {
      "@type": "MedicalCode",
      "codingSystem": "SNOMED-CT",
      "codeValue": "703272007",
      "uri": "http://snomed.info/id/703272007",
      "description": "Heart failure with reduced ejection fraction (disorder)",
      "matchType": "exactMatch"
    },
    {
      "@type": "MedicalCode",
      "codingSystem": "ICD-10-CM",
      "codeValue": "I50.2",
      "description": "Systolic (congestive) heart failure",
      "matchType": "exactMatch"
    },
    {
      "@type": "MedicalCode",
      "codingSystem": "MeSH",
      "codeValue": "D006333",
      "uri": "http://id.nlm.nih.gov/mesh/D006333",
      "description": "Heart Failure",
      "matchType": "broadMatch"
    }
  ],
  "pedagogical": {
    "target_audience": [
      "internal_medicine_residents",
      "cardiology_fellows",
      "hospitalists"
    ],
    "estimated_time": "45min",
    "difficulty_curve": 0.78,
    "learning_objectives": [
      "Name the four foundational drug classes for HFrEF",
      "State target doses for each class",
      "Identify contraindications and monitoring requirements",
      "Apply criteria for ICD and CRT",
      "Describe the benefit of early quadruple therapy initiation"
    ],
    "clinical_pearls": [
      "Start all four drug classes early at low doses rather than maximizing one at a time",
      "Only carvedilol, metoprolol succinate, and bisoprolol have mortality data",
      "36-hour washout between ACEi and ARNI to prevent angioedema",
      "SGLT2i benefits are independent of diabetes - use in all HFrEF",
      "Wait 40 days post-MI and 90 days post-revascularization before ICD"
    ],
    "board_yield": {
      "usmle_step2": "Very High - drug selection, dosing, contraindications",
      "internal_medicine_boards": "Critical - comprehensive HF management"
    }
  },
  "relationships": {
    "prerequisites": [
      {
        "id": "health-sciences:medicine:cardiology:cardio-004",
        "title": "Heart Failure Classification",
        "strength": 1.0
      }
    ],
    "skos:broader": [
      {
        "@id": "health-sciences:medicine:cardiology:cardio-004",
        "@type": "skos:Concept",
        "skos:prefLabel": "Heart Failure Classification"
      }
    ],
    "skos:related": [
      {
        "@id": "health-sciences:medicine:cardiology:cardio-039",
        "@type": "skos:Concept",
        "skos:prefLabel": "ICD Therapy"
      },
      {
        "@id": "health-sciences:medicine:cardiology:cardio-040",
        "@type": "skos:Concept",
        "skos:prefLabel": "CRT Therapy"
      }
    ],
    "owl:sameAs": [
      "http://www.wikidata.org/entity/Q181754"
    ]
  },
  "provenance": {
    "verification_status": "verified",
    "last_verified": "2026-01-11T14:28:00.000Z",
    "sources": [
      {
        "source": "2022 AHA/ACC/HFSA Heart Failure Guideline",
        "type": "clinical_guideline",
        "year": 2022,
        "confidence": 1.0
      }
    ]
  },
  "quality_assessment": {
    "CQS": 0.95,
    "completeness": 0.96,
    "accuracy": 0.97,
    "clarity": 0.94,
    "pedagogical_quality": 0.95,
    "ontology_alignment": 0.94,
    "last_assessment": "2026-01-11T14:28:00.000Z"
  },
  "owl:sameAs": "http://dbpedia.org/resource/Heart_failure",
  "skos:exactMatch": "http://www.wikidata.org/entity/Q181754"
}